-
Recent Posts
- ITC decision reversed as Chamberlain disavowed openers lacking infrared detectors
- DC grant of SJ of no literal or DOE infringement affirmed
- Appeal of IPR decision dismissed as litigation settled and “substantial risk of future infringement” not shown
- DC section 101 ineligibility decision reversed since the “the claimed invention is also directed to a non-abstract improvement”
- Remanded IPR decision reversed and vacated as “supported by…faulty reasoning”
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- Conception and Reduction to Practice
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Means-plus-function
- Method claims
- Negative Limitations
- Obviousness
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Reexamination
- Reissue
- Royalties
- Section 101 (see also Patentability)
- Software
- Summary Judgment
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- America Invents Act Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Collateral estoppel Damages Doctrine of equivalents Generics / ANDA Indefiniteness Inducement to Infringe Infringement Injunction Inter Parties Review (IPR) Inventorship IPR Means-plus-function Obviousness Obviousness-Teaching Away Patentability Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Category Archives: Inter Parties Review (IPR)
Board decision finding Google did not show anticipation or obviousness affirmed
Google LLC v. Kininklijke Philips, N.V. Docket Nos. 2018-2213 (IPR2017-00437) Moore, Bryson, Chen October 23, 2019 Non-precedential Brief Summary: Board IPR decision that Google did not show the challenged claims to be anticipated or obvious affirmed. Summary: Google appealed Board … Continue reading
PTAB denies institution of IPR against PureCircle’s steviol process claims
Sweegen, Inv. v. PureCircle USA Inc., et al. IPR2019-01017 (US 9,243,273B2) October 24, 2019 Decision not to institute IPR Brief Summary: Petition for IPR denied as PTAB determined Sweegen did not present a reasonable likelihood of prevailing on obviousness or … Continue reading
PTAB obviousness decision vacated as being improperly based on inherency
Knauf Insulation, Inc. et al. v. Rockwool International A/S Docket No. 2018-1810-11, -1891 DYK, LINN, TARANTO October 15, 2019 Non-precedential Brief Summary: PTAB inter partes reexamination obviousness determination vacated as being based on inherency. Summary: Knauf appealed PTAB’s inter partes … Continue reading
PTAB IPR decision finding OSI’s Tarceva® patent obvious reversed (e.g., “unpredictability in cancer treatment generally”, reasonable expectation of success only with hindsight)
OSI Pharmaceuticals, LLC v. Apotex Inc. et al. Docket No. 2018-1925 (IPR2016-01284) NEWMAN, TARANTO, STOLL October 4, 2019 Brief Summary: PTAB’s IPR decision holding OSI’s OB ‘221 patent obvious reversed (e.g., the PTAB “misinterpreted the asserted references”, “NSCLC treatment was … Continue reading
IPR nonobviousness decision affirmed in part because secondary evidence does not need to be “precisely limited to the point of novelty”
Henny Penny Corporation v. Frymaster LLC Docket No. 2018-1596 (IPR2016-01435) LOURIE, CHEN, STOLL September 12, 2019 Brief Summary: PTAB IPR holding of nonobviousness affirmed (no motivation to combine, secondary evidence does not need to be “precisely limited to the point … Continue reading
Posted in Inter Parties Review (IPR), IPR, Obviousness, Uncategorized
Leave a comment
Board properly decided to deny institution and dismiss IPRs on SAS remand instead of instituting on all grounds
BioDelivery Sciences Int., Inc. v. Aquesitive Therapeutics, Inc., FKA Monsol Rx, LLC Docket No. 2019-1643-45 (IPR2015-00165, -00168, -00169) NEWMAN (D), LOURIE, REYNA (Order) August 26, 2019 Brief Summary: On remand under SAS after instituting IPRs on less than all the … Continue reading
Posted in Appeal, Inter Parties Review (IPR), IPR, Uncategorized
Leave a comment
Board IPR decision vacated and remanded for erroneous claim construction; negative limitation not disclosed by prior art.
WAG Acquisition, LLC v. WebPower, Inc. et al. Docket No. 2018-1617 (IPR2016-01238) NEWMAN, CHEN, STOLL August 26, 2019 Non-precedential Brief Summary: Board IPR decision finding WAG’s claims invalid for anticipation reversed due to erroneous claim construction (e.g., the definition “comes … Continue reading